Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress

Yoshifumi Sugawara; Leslie E. Quint; Mark D. Iannettoni; Mark B. Orringer; Joseph E. Russo; Betty E. Recker; Patricia A. Saran; Richard L. Wahl

doi:10.1016/S1095-0397(99)00012-6

Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress

Yoshifumi Sugawara, Leslie E. Quint, Mark D. Iannettoni, Mark B. Orringer, Joseph E. Russo, Betty E. Recker, Patricia A. Saran, Richard L. Wahl

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Objective: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis. Methods: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared. Results: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p = .0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean ≤ 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p = .2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean. Conclusion: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.

Original language	English (US)
Pages (from-to)	111-118
Number of pages	8
Journal	Clinical Positron Imaging (Netherlands)
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/S1095-0397(99)00012-6
State	Published - 1999
Externally published	Yes

Keywords

2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG)
Emission Computed Tomography
Non-small Cell Lung Cancer
Positron Emission Tomography (PET)
Prognosis
Standardized Uptake Value (SUV)

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/S1095-0397(99)00012-6

Cite this

@article{2e08ba66a86e4570ac7e819f208418d8,

title = "Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress",

abstract = "Objective: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis. Methods: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared. Results: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p = .0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean ≤ 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p = .2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean. Conclusion: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.",

keywords = "2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG), Emission Computed Tomography, Non-small Cell Lung Cancer, Positron Emission Tomography (PET), Prognosis, Standardized Uptake Value (SUV)",

author = "Yoshifumi Sugawara and Quint, {Leslie E.} and Iannettoni, {Mark D.} and Orringer, {Mark B.} and Russo, {Joseph E.} and Recker, {Betty E.} and Saran, {Patricia A.} and Wahl, {Richard L.}",

note = "Funding Information: This work was supported by the National Institute of Health grants CA 52880, CA 53172, CA 56731 and M01RR00042, and the “Hi-tech funding initiative” of the University of Michigan Clinical Research Center. The authors thank Paul V. Kison, BS, for his technical assistance.",

year = "1999",

doi = "10.1016/S1095-0397(99)00012-6",

language = "English (US)",

volume = "2",

pages = "111--118",

journal = "Clinical Positron Imaging (Netherlands)",

issn = "1095-0397",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress

AU - Sugawara, Yoshifumi

AU - Quint, Leslie E.

AU - Iannettoni, Mark D.

AU - Orringer, Mark B.

AU - Russo, Joseph E.

AU - Recker, Betty E.

AU - Saran, Patricia A.

AU - Wahl, Richard L.

N1 - Funding Information: This work was supported by the National Institute of Health grants CA 52880, CA 53172, CA 56731 and M01RR00042, and the “Hi-tech funding initiative” of the University of Michigan Clinical Research Center. The authors thank Paul V. Kison, BS, for his technical assistance.

PY - 1999

Y1 - 1999

N2 - Objective: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis. Methods: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared. Results: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p = .0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean ≤ 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p = .2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean. Conclusion: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.

AB - Objective: To determine if the intensity of fluorine-18-fluorodeoxyglucose (FDG) uptake in primary non-small cell lung cancer (NSCLC) could independently predict patient prognosis. Methods: Thirty-eight patients with untreated NSCLC were studied with FDG-PET. Primary tumor FDG uptake was calculated by the standardized uptake value based on lean body mass (SUV-lean). Cumulative survival rate and the SUV-lean were compared. Results: There were no significant differences between the tumor stages and the SUV-lean. Although the survival rates significantly decreased as the stage progressed (p = .0049), there was no significant difference in the survival rate between the group with lower primary tumor FDG uptake (SUV-lean ≤ 8.72) and the group with higher tumor FDG uptake (SUV-lean > 8.72) (p = .2256). However, in the subset of patients without metastasis, survival tended to be longer with a lower tumor SUV-lean. Conclusion: In this population of patients with NSCLC, the tumor FDG uptake does not independently predict the prognosis.

KW - 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG)

KW - Emission Computed Tomography

KW - Non-small Cell Lung Cancer

KW - Positron Emission Tomography (PET)

KW - Prognosis

KW - Standardized Uptake Value (SUV)

UR - http://www.scopus.com/inward/record.url?scp=0000716072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000716072&partnerID=8YFLogxK

U2 - 10.1016/S1095-0397(99)00012-6

DO - 10.1016/S1095-0397(99)00012-6

M3 - Article

AN - SCOPUS:0000716072

SN - 1095-0397

VL - 2

SP - 111

EP - 118

JO - Clinical Positron Imaging (Netherlands)

JF - Clinical Positron Imaging (Netherlands)

IS - 2

ER -

Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A work in progress

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this